The novel capsazepine analog, CIDD‐99, significantly inhibits oral squamous cell carcinoma in vivo through a TRPV1‐independent induction of ER stress, mitochondrial dysfunction, and apoptosis

Background Oral squamous cell carcinoma (OSCC) is a deadly disease with a mere 40% five‐year survival rate for patients with advanced disease. Previously, we discovered that capsazepine (CPZ), a transient receptor potential channel, Vanilloid subtype 1 (TRPV1) antagonist, has significant anti‐tumor...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of oral pathology & medicine 2019-05, Vol.48 (5), p.389-399
Hauptverfasser:	De La Chapa, Jorge J., Singha, Prajjal K., Self, Kristen K., Sallaway, McKay L., McHardy, Stanton F., Hart, Matthew J., McGuff, Howard Stan, Valdez, Matthew C., Ruiz, Francisco, Polusani, Srikanth R., Gonzales, Cara B.
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Apoptosis Calcium imaging Capsaicin - analogs & derivatives Capsaicin - pharmacology Capsaicin receptors Capsazepine capsazepine analog Carcinoma, Squamous Cell - drug therapy Cell cycle Cell Line, Tumor Cell proliferation Depolarization Endoplasmic Reticulum Stress Female Humans Isoquinolines - pharmacology Male Mice Mice, Nude Mitochondria Mitochondria - drug effects Mitochondria - pathology Mouth Neoplasms - drug therapy Oral cancer Oral squamous cell carcinoma Pain Rats Rats, Sprague-Dawley Squamous cell carcinoma Transient receptor potential proteins TRPV Cation Channels - antagonists & inhibitors Tumors Xenograft Model Antitumor Assays Xenografts
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!